Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1112MR)

This product GTTS-WQ1112MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1112MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14234MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ4275MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ8275MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ14029MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ1021MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ1687MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ7164MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ2585MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW